ArticleClinical and vaccine immunology : CVI2006
Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation.
Article in Clinical and vaccine immunology : CVI, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality.The Journal of infectious diseases · 2007Trial
- Clinical Characteristics and Risk Factors for Cryptococcal Meningitis in Non-Acquired Immunodeficiency Syndrome Patients with Pulmonary Cryptococcosis: A 12-Year Hospital-Based Study.Pathogens (Basel, Switzerland) · 2026Article
- Shared and unique antibody and B cell profiles in HIV-positive and HIV-negative individuals with cryptococcal meningoencephalitis.Medical mycology · 2023Article
- Article
- Review
- Identification of Disease-Associated Cryptococcal Proteins Reactive With Serum IgG From Cryptococcal Meningitis Patients.Frontiers in immunology · 2021Article
- Pathogen and host genetics underpinning cryptococcal disease.Advances in genetics · 2020Review
- Antibody immunity and natural resistance to cryptococcosis.Current tropical medicine reports · 2019Article
- Association Between Plasma Antibody Responses and Risk for Cryptococcus-Associated Immune Reconstitution Inflammatory Syndrome.The Journal of infectious diseases · 2019Article
- Antibody Responses in HIV-Infected Patients With Advanced Immunosuppression and Asymptomatic Cryptococcal Antigenemia.Open forum infectious diseases · 2019Article
- Antibody and B Cell Subset Perturbations in Human Immunodeficiency Virus-Uninfected Patients With Cryptococcosis.Open forum infectious diseases · 2018Article
- Article
- Immunology of Cryptococcal Infections: Developing a Rational Approach to Patient Therapy.Frontiers in immunology · 2018Review
- Innate Immune Responses toJournal of fungi (Basel, Switzerland) · 2017Article
- Capsular specific IgM enhances complement-mediated phagocytosis and killing of Cryptococcus neoformans by methamphetamine-treated J774.16 macrophage-like cells.International immunopharmacology · 2017Article
- Host immunity to Cryptococcus neoformans.Future microbiology · 2015Review
- Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.Cell host & microbe · 2012Review
- The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans.Infection and immunity · 2010Article
- IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status.The Journal of infectious diseases · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Cryptococcosis is an important complication of solid-organ transplantation, but the risk factors for disease are poorly understood. The goal of this study was to investigate whether specific or nonspecific serum immunoglobulin levels determined in samples obtained before and after solid-organ transplantation differed in patients who did or did not develop cryptococcosis after transplantation. We analyzed pretransplantation sera from 25 subjects, 15 who subsequently developed cryptococcosis and 10 who did not, and posttransplantation sera from 24 subjects, 13 who developed cryptococcosis and 11 who did not. All subjects received a tacrolimus-based immunosuppressive regimen. Total immunoglobulin levels were measured by immunodiffusion, and Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM)-specific serum antibody levels were determined by enzyme-linked immunosorbent assays. The results showed that solid-organ transplantation had a significant effect on total immunoglobulin and GXM-reactive antibody levels. GXM-reactive antibody levels differed in subjects who did and did not develop cryptococcosis. In pretransplant serum samples, the levels of GXM-reactive immunoglobulin M (IgM) were significantly lower in subjects who developed cryptococcosis after transplantation than in those who did not. For posttransplant serum samples, the levels of GXM-reactive IgM and IgG were significantly higher among the subjects who developed cryptococcosis than among those who did not. These findings suggest that perturbations in the preexisting antibody or B-cell repertoire and/or related to treatment of rejection, transplantation, or immunosuppressive therapy could translate into an increased risk for transplant-associated cryptococcosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.